Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Fri, 28.06.2024
Einhell Germany AG
Q2 prelims in line with expectations // FY24e guidance confirmed
Yesterday, Einhell released ad-hoc news revealing that sales between
January and May 2024 amounted to € 478.2m (+11.6% yoy). The company further
expects sales for H1'24 to be € 565m (+7.4% yoy; eNuW: € 562m) and EBT
margin to be 8.5% (-10bps yoy; eNuW: 8.3%). Theref [ … ]
Thu, 27.06.2024
Nabaltec AG
Further op. improvements // FY guidance conservative
Topic: Despite the recent 30% share price increase since the low in March,
Nabaltec remains on our Alpha List with the key reasons for it being (1)
further operational improvements in Q2 and a too conservative FY guidance,
(2) the promising optionality of boehmite and (3) an attractive valuat [ … ]
Wed, 26.06.2024
UmweltBank AG
- Return to profitability expected after transformation year 2024
- Realignment bears fruit
- Interest margin expected to bottom out
With the publication of their 2023 Annual Report, UmweltBank AG has
confirmed the preliminary figures published in March. As previously
announced, new lending business declined and was down from the previous
[ … ]
Wed, 26.06.2024
Westwing Group SE
On track to strengthen the premium H&L one-stop shop in 2024
While 2024 revenue and active customer growth will be affected by
headwinds in its International segment resulting from a deliberate and
strategic adjustment of the product assortments in Spain and Italy by a low
to mid single-digit percentage figure to enhance future scalability [ … ]
Mon, 24.06.2024
Verve Group SE
Jun acquisition ensures significant sales and earnings growth and a
significant strengthening of the demand side; the integration of the
acquisition opens up considerable sales synergies; significant increase in
forecasts and price target; 'BUY' rating confirmed
On 18 June 2024, Verve Group SE (Verve) announced the signing of an
agreement [ … ]
Mon, 24.06.2024
APONTIS PHARMA AG
First Berlin Equity Research on 24/06/2024 initiated coverage on APONTIS
PHARMA AG (ISIN: DE000A3CMGM5/ Bloomberg: APPH GR). Analyst Christian
Orquera placed a BUY rating on the stock, with a EUR 17.00 price target.
Abstract:
Apontis Pharma AG (Apontis) is a leading specialty pharmaceutical company
focusing on the development and marketing of a [ … ]
Mon, 24.06.2024
Verve Group SE
First Berlin Equity Research hat ein Research Update zu Verve Group SE
(ISIN: SE0018538068) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 4,10 auf EUR 4,90.
Zusammenfassung:
Die kürzlich umbenannte Verve Group SE hat mit der strategischen Übernahme
der Jun Group, ein [ … ]
Wed, 19.06.2024
LAIQON AG
High debt-to-equity conversion and successful capital increase
Topic: in May, LAIQON's 20/24 convertible showed a 80% conversion rate and
a 5.3% cash capital increase has been placed successfully at a premium.
Both capital measures underpin the investor's appetite for LAIQON's equity
story.
High debt to equity conversion: the conversion windo [ … ]
Tue, 18.06.2024
Flughafen Wien AG
Solid May'24 traffic results kick off strong summer; chg. est.
Topic: FWAG released strong May 2024 traffic results, which came in
slightly above our expectations and signal solid ongoing demand for air
travel.
Solid passenger growth: In May, group passenger numbers rose by 8% yoy to
3.75m, above our estimate of 3.66m. FWAG's main hub (Vienna [ … ]
Fri, 14.06.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and increased the price target from USD 3.60 to
USD 8.50.
Abstract:
Cardiol Therapeutics (Cardiol) announced excellent topline data for its
phase II open-label pilot US study (MAvERI [ … ]